Zafirlukast
- Generic Name
- Zafirlukast
- Brand Names
- Accolate
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33N3O6S
- CAS Number
- 107753-78-6
- Unique Ingredient Identifier
- XZ629S5L50
- Background
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.
Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
- Indication
For the prophylaxis and chronic treatment of asthma.
- Associated Conditions
- Asthma, Chronic Urticaria
- Associated Therapies
- -
Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Allergy & Asthma Medical Group & Research Center
- Target Recruit Count
- 12
- Registration Number
- NCT06069063
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04339140
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 4
- Registration Number
- NCT02950480
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 44
- Registration Number
- NCT01283061
- Locations
- 🇮🇳
BA Research India Ltd., Ahmedabad, Bodakdev, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.